These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 10174423)

  • 21. Use 'TRU' (total resource utilization) data to evaluate utilization, disease costs.
    Data Strateg Benchmarks; 1999 Dec; 3(12):177-80. PubMed ID: 11009930
    [No Abstract]   [Full Text] [Related]  

  • 22. Analysis of claims data provides extra punch for disease management efforts.
    Healthc Demand Dis Manag; 1998 Dec; 4(12):189-91. PubMed ID: 10339126
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gastrointestinal illness in managed care: healthcare utilization and costs.
    Lim D; Farup C; Lawrence BJ; Sorrell L; Dubois RW; Zeldis JB
    Am J Manag Care; 1997 Dec; 3(12):1859-72. PubMed ID: 10178475
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Utilization management following health care reform: eight recommendations for managed care.
    Lewis AB; Lamprey J
    AAPPO J; 1993; 3(2):11-6, 41-2. PubMed ID: 10148616
    [No Abstract]   [Full Text] [Related]  

  • 25. A look at cost-effectiveness.
    Gibaldi M; Sullivan SD
    Pharmacotherapy; 1994; 14(4):399-414. PubMed ID: 7937277
    [No Abstract]   [Full Text] [Related]  

  • 26. Clinical and economic considerations of coronary heart disease: a managed care approach. Proceedings based on presentations from two conferences, Cardiovascular Event Reduction: Defining the Role of HMG Therapy in Managed Care, held November 14-16, 1997 in Philadelphia, and Pharmacoeconomics & Outcomes Issues of Lipid Therapy, held November 5-7, 1997 in Orlando.
    Am J Manag Care; 1998 Apr; 4(4 Suppl):S168-233. PubMed ID: 10180343
    [No Abstract]   [Full Text] [Related]  

  • 27. [Drug committees welcome the SBU hypertension report. A number of patients can be offered cost-effective, evidence-based therapy].
    Ohlsson O
    Lakartidningen; 2004 Dec; 101(49):3984-5. PubMed ID: 15633336
    [No Abstract]   [Full Text] [Related]  

  • 28. Containing pharmacy costs: back to basics.
    Giaquinta D
    Manag Care Interface; 1999 Oct; 12(10):56-7. PubMed ID: 10623008
    [No Abstract]   [Full Text] [Related]  

  • 29. [Health economic evaluation of recommended drug treatment].
    Jendteg S; Persson U; Anell A
    Lakartidningen; 2002 Jul; 99(30-31):3130-1. PubMed ID: 12198934
    [No Abstract]   [Full Text] [Related]  

  • 30. A focus on the asthma HEDIS measure and its implications for clinical practice.
    Davies TJ; Bunn WB; Fromer L; Gelfand EW; Colice GL
    Manag Care Interface; 2006 Feb; 19(2):29-36. PubMed ID: 16529078
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differences in medical expenditure according to drug prices.
    Ueshima H
    Hypertens Res; 2006 May; 29(5):301-2. PubMed ID: 16832148
    [No Abstract]   [Full Text] [Related]  

  • 32. Use of randomized controlled trials in organizational decision making: a cost-minimization approach.
    Cher DJ; Maclure M
    Am J Manag Care; 2000 Aug; 6(8):894-904. PubMed ID: 11186501
    [No Abstract]   [Full Text] [Related]  

  • 33. Constructing disease management programs.
    Gurnee MC; Da Silva RV
    Manag Care; 1997 Jun; 6(6):67-70, 75-6. PubMed ID: 10168650
    [No Abstract]   [Full Text] [Related]  

  • 34. [Pharmacotherapy of hypertension. How much can safely be saved?].
    Anlauf M
    MMW Fortschr Med; 2004 Apr; 146(15):57-8. PubMed ID: 15373022
    [No Abstract]   [Full Text] [Related]  

  • 35. The case for a value-based formulary: striving for total lowest net cost.
    Weart W; Bauman GR
    Manag Care Interface; 2007 Apr; 20(4):42-7. PubMed ID: 17474330
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The heptavalent conjugate pneumococcal vaccine and its implications for managed care--clinical overview and roundtable discussions.
    Alexander PG; Chartrand SA; Davies TJ; Gaines BM; Oster G; Shurin P; Tamsky L; Thornton DK; Wittert W
    Manag Care Interface; 2001; Suppl C():10-28; quiz 29-30. PubMed ID: 11724029
    [No Abstract]   [Full Text] [Related]  

  • 37. Assessing step-therapy programs:a step in the right direction.
    Gleason PP
    J Manag Care Pharm; 2007 Apr; 13(3):273-5. PubMed ID: 17407393
    [No Abstract]   [Full Text] [Related]  

  • 38. How well does your PBM perform?
    McCarthy R
    Bus Health; 1999 Jan; 17(1):24-9. PubMed ID: 10345211
    [No Abstract]   [Full Text] [Related]  

  • 39. Recommendations for best practices in the treatment of Alzheimer's disease in managed care.
    Fillit HM; Doody RS; Binaso K; Crooks GM; Ferris SH; Farlow MR; Leifer B; Mills C; Minkoff N; Orland B; Reichman WE; Salloway S
    Am J Geriatr Pharmacother; 2006; 4 Suppl A():S9-S24; quiz S25-S28. PubMed ID: 17157793
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The road ahead for Medicare managed care: addressing the needs of the chronically ill.
    Tompkins C; Wallack SS; Skwara KC
    J Long Term Home Health Care; 1998; 17(2):11-20. PubMed ID: 10180116
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.